title: Power analysis for case-control association studies of samples with known family histories.
abstract: Genome-wide case-control studies have been widely used to identify genetic variants that predispose to human diseases. Such studies are powerful in detecting common genetic variants with moderate effects, but quickly lose power as allele frequency and genotype relative risk decrease. Because patients with one or more affected relatives are more likely to inherit disease-predisposing alleles of a genetic disease than patients without family histories of the disease, sampling patients with affected relatives almost always increases the frequency of disease predisposing alleles in cases and improves the power of case-control association studies. This paper evaluates the power of case-control studies that select cases and/or controls according to their family histories of disease. Our results showed that this study design can dramatically increase the power of a case-control association study for a wide range of disease types. Because each additional affected relative of a patient reduces the required sample size roughly by a pair of case and control, inclusion of cases with affected relatives can dramatically decrease the required sample size and thus the cost of such studies.
authors.affiliation: Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, 1155 Pressler St. Unit 1340, Houston, TX 77030, USA. bpeng@mdanderson.org
authors.forename: Bo
authors.initials: B
authors.lastname: Peng
authors.forename: Biao
authors.initials: B
authors.lastname: Li
authors.forename: Younghun
authors.initials: Y
authors.lastname: Han
authors.forename: Christopher I
authors.initials: CI
authors.lastname: Amos
mesh_terms: D000483:Alleles; D016022:Case-Control Studies; D005787:Gene Frequency; D030342:Genetic Diseases, Inborn / Q000235:genetics*; D005838:Genotype; D006801:Humans; D012106:Research; D012107:Research Design; D012306:Risk; D018401:Sample Size
references.citation: Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4340-5
references.pmid: 18326623
references.citation: Hum Genet. 2003 Apr;112(4):434-5
references.pmid: 12574941
references.citation: Cell Cycle. 2005 Apr;4(4):521-5
references.pmid: 15753653
references.citation: Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3770-4
references.pmid: 16537453
references.citation: Br J Cancer. 2005 Oct 3;93(7):825-33
references.pmid: 16160696
references.citation: Nat Genet. 2008 Mar;40(3):316-21
references.pmid: 18264097
references.citation: Hum Mol Genet. 2007 Oct 15;16 Spec No. 2:R220-5
references.pmid: 17597095
references.citation: Nature. 2008 Nov 6;456(7218):18-21
references.pmid: 18987709
references.citation: J Clin Invest. 2008 May;118(5):1590-605
references.pmid: 18451988
references.citation: Genome Res. 2006 Jun;16(6):693-701
references.pmid: 16741161
references.citation: Nat Genet. 2006 Feb;38(2):209-13
references.pmid: 16415888
references.citation: Nature. 2007 Jun 28;447(7148):1087-93
references.pmid: 17529967